Phase 3 Antibody Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche152 enrolled82 locationsNCT05271409
Recruiting
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Antibody-mediated Rejection
Biogen120 enrolled59 locationsNCT06685757
Recruiting
Phase 3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 3
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisEnd Stage Renal Disease
Centre Hospitalier Departemental Vendee136 enrolled58 locationsNCT03323476
Recruiting
Phase 3
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Antibody-mediated Rejection
Vastra Gotaland Region50 enrolled8 locationsNCT04561986